Latest News and Press Releases

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics to participate in the 44th Annual J.P. Morgan Healthcare Conference

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics announces proposed public offering of Class A common stock.

Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4).

Vera Therapeutics appoints veteran biotech executive James R. Meyers to its Board of Directors.

Vera Therapeutics' management team will present and participate in one-on-one meetings at upcoming investor conferences.

Vera Therapeutics' management team will present at the TD Cowen Immunology & Inflammation Summit (Nov. 12-13, 2025).

Vera Therapeutics Submits BLA to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgAN